殷學(xué)明

[摘要] 目的 探究復(fù)方異丙托溴銨與布地奈德共同使用通過霧化吸入治療應(yīng)用于慢阻肺治療的臨床效果。方法 方便選取2017年8月—2018年8月時間段至該院就診的45例慢阻肺患者作為該次研究的研究對象。以計算機軟件分組將其分為單一組（22例，單一布地奈德吸入治療）和聯(lián)合組（23例，復(fù)方異丙托溴銨聯(lián)合布地奈德吸入治療），對比兩組肺功能以及血氣分析指標(biāo)的變化。結(jié)果 治療前，兩組患者的肺功能指標(biāo)以及血氣分析指標(biāo)均差異無統(tǒng)計學(xué)意義（t=0.886、0.317，P=0.190、0.376）。治療后，聯(lián)合組FEV1（2.04±0.58）L、FVC/FEV1（58.62±8.41）%明顯高于單一組（1.45±0.47）L、（50.28±8.67）%（t=3.739、3.276，P=0.000、0.001）。治療前，兩組血氣分析指標(biāo)均差異無統(tǒng)計學(xué)意義（t=0.180、0.345，P=0.429、0.366）。聯(lián)合組血PaCO2（7.58±0.55）kPa、PaO2（11.02±1.74）kPa明顯優(yōu)于單一組（8.04±0.87）kPa、（9.64±2.39）kPa（t=2.130、2.222，P=0.019、0.016）。結(jié)論 復(fù)方異丙托溴銨聯(lián)合布地奈德吸入應(yīng)用于慢阻肺治療的優(yōu)勢更明顯，可明顯改善患者肺功能，有利于血氣變化，提高臨床治療效果值得臨床推廣。

[關(guān)鍵詞] 復(fù)方異丙托溴銨;布地奈德;霧化吸入治療;慢阻肺;肺功能;血氣分析

[中圖分類號] R563.8;R563.9? ? ? ? ? [文獻標(biāo)識碼] A? ? ? ? ? [文章編號] 1674-0742（2020）07（c）-0104-03

[Abstract] Objective To explore the clinical effect of compound ipratropium bromide and budesonide used in the treatment of COPD by nebulized inhalation therapy. Methods Forty-five patients with COPD who visited the hospital from August 2017 to August 2018 were convenient selected as the subjects of this study. Computer software was used to divide it into a single group （22 cases， single budesonide inhalation therapy） and a combined group （23 cases， compound ipratropium bromide combined with budesonide inhalation therapy）， comparing the lung function and blood gas analysis changes in indicators of the two groups on two groups. Results Before treatment， the lung function indexes and blood gas analysis indexes of the two groups were not statistically significantly different（t=0.886， 0.317， P=0.190， 0.376）. After treatment， the combined group FEV1 （2.04±0.58） L， FVC/FEV1 （58.62±8.41）% was significantly higher than the single group （1.45±0.47） L， （50.28±8.67）% （t=3.739， 3.276， P=0.000， 0.001）. Before treatment， there was no statistically significant difference in blood gas analysis indexes between the two groups （t=0.180， 0.345， P=0.429， 0.366）. The blood PaCO2（7.58±0.55） kPa and PaO2 （11.02±1.74） kPa of the combined group were significantly better than the single group （8.04±0.87） kPa and （9.64±2.39） kPa （t=2.130， 2.222， P=0.019，0.016）. Conclusion Compound ipratropium bromide combined with budesonide inhalation has more obvious advantages in the treatment of COPD. It can significantly improve the patient's lung function， is conducive to blood gas changes， and it is worth clinical promotion to improve the clinical treatment effect.

[Key words] Compound ipratropium bromide; Budesonide; Nebulized inhalation therapy; COPD; Lung function; Blood gas analysis